So, you think Bavi works slow with docetaxel only? By the way, working slow doesn't necessarily affect ORR, just the time to get to ORR. ORR as primary endpoint affects how they size the trial, and maybe how randomization is done. Missing ORR primary endpoint means bavi anti-cancer activity is weaker than trial designer assumed.
I am done with my argument on this subject. The last time I spent this much time arguing about one trial on message board was PARD's picoplatin in SCLC when many were so sure about trial result.
Market Data 
Markets 
AI
